Skip to main content

2 posts tagged with "Epidemiology"

Population-level prevalence, incidence, and burden-of-disease data for mental disorders.

View All Tags

Issue #005 — JAMA Pediatrics puts a peer-reviewed number on the demand side: ~20% of US youth now use AI chatbots for mental-health advice, and 63% hide it.

Software engineer & researcher

Weekly Intelligence · Week 5 · 5 June 2026 · Issue #005

A new JAMA Pediatrics survey puts a peer-reviewed number on the demand side: ~20% of US 12–21-year-olds used AI chatbots for mental-health advice in 2025, up from 13% a year earlier, and 63% disclosed it to no one.


Executive Summary

This was a quiet week for primary detection research and a sharp one for measuring the demand side. The single firmly-dated, peer-reviewed development is McBain et al., AI Chatbot Use and Disclosure for Mental Health Among US Adolescents and Young Adults, published in JAMA Pediatrics on 3 June 2026 — a nationally-weighted survey (1,009 respondents aged 12–21, fielded November 2025, weighted to ≈42 million US youth) finding that 19.2% had used AI chatbots for mental-health advice in 2025, up from 13.1% the prior year, with a striking 63.3% disclosing that use to no one. The study converts threads this newsletter has tracked qualitatively and via single-session conference figures (the Drexel "bond paradox," Issue #004; the JHU "AI for Hope" 5-million-young-people estimate, Issue #004; the 16%-of-adults figure, Issue #001) into a peer-reviewed, demographically-stratified denominator — and adds a genuinely new variable, non-disclosure, that detection and clinical-intake pipelines have not previously been able to size. No new wearable, speech, or multimodal primary results cleared the 7-day window; several candidate papers surfaced in search but date to February–April 2026 (e.g. a Journal of Affective Disorders acoustic-biomarker analysis) or were already covered (the Mindcraft adolescent digital-phenotyping feasibility study, Issue #001), and are held out. The honest read: the field's measurement frontier was static this week, but the best evidence yet on how many young people are using these tools, how often, and how secretly landed in a top journal.


Key Metrics

MetricValueSource
US youth (12–21) using AI chatbots for mental-health advice, 2025 vs 202419.2% vs 13.1%McBain et al. · JAMA Pediatrics · 3 Jun 2026
Users who disclosed the chatbot use to no one63.3%McBain et al. · JAMA Pediatrics · 3 Jun 2026
Users finding the experience helpful / using ≥ monthly91.7% / >40%McBain et al. · JAMA Pediatrics · 3 Jun 2026

Clinical Translation & Help-Seeking Behavior

JAMA Pediatrics: ~20% of US youth use AI chatbots for mental-health advice — and 63% hide it

A team led by Ryan K. McBain (RAND), with collaborators at Harvard Medical School and the MIT Media Lab, surveyed a nationally representative sample of 1,009 US adolescents and young adults aged 12–21 in November 2025, statistically weighted to represent roughly 42 million youth. The headline: 19.2% reported using AI chatbots for mental-health advice during 2025 — an estimated 8.2 million young people — up sharply from 13.1% in the equivalent 2024 survey. Of those users, 63.3% had not disclosed the practice to anyone; more than 40% used a chatbot for such advice at least monthly and 5.8% did so daily or almost daily; and 91.7% rated the experience as helpful. Use was higher among girls and young women, among older teens, and among those who had recently consulted a physician about mental health. The authors caution that the high perceived helpfulness may reflect chatbots' tendency to be overly agreeable or flattering rather than the accuracy of the advice — the same sycophancy-and-reassurance failure mode the Mpathic benchmark (Issue #002) and the Drexel "bond paradox" (Issue #004) characterised from the model and relational-behavior sides respectively. For this newsletter the new and load-bearing variable is non-disclosure: a near-two-thirds hidden-use rate means clinician-intake screening for chatbot use (the WBUR / JAMA Psychiatry intake practice flagged in Issue #001) will systematically under-count exposure unless it is actively and non-judgmentally prompted, and it sets a hard ceiling on how much of this behavior any passively-observed clinical signal can currently see.

Source: McBain RK, et al. · JAMA Pediatrics · 3 Jun 2026 · 10.1001/jamapediatrics.2026.2015 Source: Medical Xpress · "1 in 5 teens turn to AI chatbots for mental health advice…" · 3 Jun 2026 · medicalxpress.com Source: American Journal of Managed Care · "AI Chatbot Use for Mental Health Advice Rises Sharply Among US Youth" · Jun 2026 · ajmc.com


Forward Outlook

  • Near-term: The 63% non-disclosure figure is the citable number that turns "ask patients about chatbot use" from a recommendation into a screening-design requirement. Expect it to appear quickly in intake-questionnaire guidance and in the state-legislative testimony tracked since Issue #001 (Utah HB 452) and Issue #004 (the 800-bill / 3-enacted review) — hidden use by minors is the most legible argument for disclosure mandates.
  • Mid-term: Paired with the GBD 2023 adolescent-peak shift (Issue #003), the McBain prevalence trajectory (13% → 19% in one year) strengthens the case for the triage-grade, human-in-the-loop deployment shape this newsletter has argued toward — and specifically for routing-into-care designs over autonomous companionship, given that the heaviest, most hidden use sits in exactly the cohort with the fastest-rising burden.
  • Long-term: Non-disclosure is now a measured ceiling on observational detection. If most at-risk chatbot use is invisible to clinicians and to passive sensing alike, the field's early-detection value increasingly depends on instrumentation inside the chatbot surface (guardrails, bond-paradox-aware routing, VERA-MH / Mpathic-style safety evaluation) rather than on external behavioral signals catching the behavior after the fact.

Sources used: 3 · Week 5 · Next issue: 12 June 2026

Issue #003 — The Lancet's GBD 2023 update lands 1.2B globally with anxiety up 158% since 1990, and Spring Health's VERA-MH crystallises as the open-source safety benchmark The Path used to anchor its $14.3M launch.

Software engineer & researcher

Weekly Intelligence · Week 3 · 23 May 2026 · Issue #003

The Lancet's GBD 2023 update lands 1.2B globally with anxiety up 158% since 1990, and Spring Health's VERA-MH crystallises as the open-source safety benchmark The Path used to anchor its $14.3M launch.


Executive Summary

This was an epidemiology- and industry-positioning week. The most consequential signal is The Lancet's Updated trends in the global prevalence and burden of mental disorders, 1990–2023 — a Global Burden of Disease 2023 systematic analysis across 204 countries — putting the worldwide prevalence of mental disorders at ≈1.2 billion in 2023, a 95.5% increase since 1990, with anxiety and depression registering 158% and 131% growth respectively over that window. The 15-to-19 age band is, for the first time in GBD history, the peak-burden cohort. On the industry side, two interlinked announcements on 21 May reframe how mental-health AI products will go to market: Tony-Robbins-co-founded The Path exited stealth with a $14.3M seed (Prime Movers Lab–led) and positioned itself by self-reporting a score of 95 on VERA-MH, the open-source Spring Health / Expert Council evaluation that has emerged this spring as the field's first openly-licensed multi-turn clinical-safety benchmark for mental-health LLMs (distinct from last week's Mpathic clinician-built suite, which is not open-sourced). The week is short on new primary research but long on infrastructure: a population-level prevalence baseline and an evaluation primitive that challengers can now build against.


Key Metrics

MetricValueSource
GBD 2023 global mental-disorder prevalence (2023)1.2 billionThe Lancet · 21 May 2026
GBD 2023 anxiety / MDD growth since 1990+158% / +131%The Lancet · 21 May 2026
The Path seed round / claimed VERA-MH score$14.3M / 95 of 100TechCrunch · 21 May 2026

Epidemiology

Lancet GBD 2023: global mental-disorder burden reaches 1.2B, peak shifts into the 15–19 cohort

The Institute for Health Metrics and Evaluation–led Global Burden of Disease 2023 mental- disorder update was published in The Lancet on 21 May 2026 and is the field's first major post-pandemic systematic re-baseline. The analysis covers 12 mental-disorder categories across 204 countries and territories from 1990 to 2023. Headline findings: prevalence reaches ≈1.2 billion globally in 2023, a 95.5% rise since 1990; anxiety disorders grew 158% and major depressive disorder 131% over the same period, jointly the world's two most common mental-health conditions. For the first time in GBD history the peak-burden cohort is the 15-to-19 age band, displacing the previously dominant young-adult window — a structural shift the authors flag as "a more concerning phase of worsening mental disorder burden globally." Female burden is disproportionate across the lifespan. The paper functions as the new denominator the computational-behavioral-detection literature should be sized against: the gap between detection research throughput and the at-risk adolescent population it nominally serves is now larger than any prior GBD wave has reported, and the case for scalable early-detection pipelines (passive, unobtrusive, school-deployable) — rather than clinic-bound assessment — is incrementally strengthened by the demographic shift alone.

Source: GBD 2023 Mental Disorders Collaborators · The Lancet · 21 May 2026 · 10.1016/S0140-6736(26)00519-2 Source: Brenda Goodman · CNN Health · 21 May 2026 · cnn.com


AI / ML for Mental Health Detection

VERA-MH emerges as the first open-source clinician-rubric benchmark a new entrant has scored against

The Spring Health / Expert Council benchmark Validation of Ethical and Responsible AI in Mental Health (VERA-MH) — first proposed in late 2025 and now in its 60-day Request for Comment phase — is the first openly-licensed multi-turn evaluation rubric for mental-health LLMs and is methodologically distinct from last week's Mpathic clinician-built suite (Issue #002), which is not open-sourced and is held by a single vendor. VERA-MH uses a clinically-developed rubric applied by an LLM-as-judge against synthetic multi-turn role-plays grounded in evidence-based suicide-prevention practice; preliminary validation reports an inter-clinician inter-rater reliability of 0.77 and an LLM-judge–to-clinical-consensus agreement of 0.81. Spring Health's own deployed system scored 82/100. The benchmark's structural contribution this week is not the numbers themselves but the category: a non-vendor, open-source, multi-turn safety evaluation challengers can now publicly score against — a primitive the chatbot field has so far lacked. The release timing is significant: 21 May saw the first third-party product (The Path; see Industry section) anchor a launch on a self-reported VERA-MH score, indicating the benchmark is moving from proposal to industry adoption inside one quarter.

Source: Spring Health · "Spring Health and Expert Council Release VERA-MH, the First Open-Source Evaluation for Validating AI in Mental Health" · 2026 · springhealth.com Source: VERA-MH preprint · arXiv · 2026 · arXiv:2602.05088

⚠️ Preprint — not yet peer reviewed


Industry and Product News

The Path closes $14.3M seed, exits stealth with self-reported VERA-MH score of 95

The Path, a Tony-Robbins-co-founded AI mental-health platform built by former Calm leadership (data-science / AI head Anson Whitmer and engineering head Tyler Sheaffer), exited stealth on 21 May with a $14.3M seed round led by Prime Movers Lab (where Robbins is a partner). The product offers eleven configurable AI "therapists," is free at launch with a planned $40/month tier, and has handled ≈3.5M messages across ~50,000 users since soft launch. The most relevant detail for this newsletter is positional: The Path is the first stealth-exit product this cycle to anchor its launch communication on a self-reported VERA-MH safety score (95 of 100), with the press release directly contrasting that figure against a "top score of 65 for consumer bots." The release is consequential less for the round size than for the new market entry pattern it codifies: the safety-benchmark-self-report is now a launch-narrative primitive on the same axis as efficacy claims and clinician-endorsement claims, which is the position FDA digital-health advisers and the AMA's April letter to Congress (covered as background in earlier issues) have been pushing for over the last six months. Expect competing entrants and incumbents (Wysa, Woebot, Replika, Character.AI) to publish VERA-MH scores within weeks — and a parallel pattern to emerge for the Mpathic suicide benchmark — as not doing so becomes a negative inference.

Source: Marina Temkin · TechCrunch · 21 May 2026 · techcrunch.com Source: MobiHealthNews · 21 May 2026 · mobihealthnews.com Source: HIT Consultant · 21 May 2026 · hitconsultant.net


Forward Outlook

  • Near-term: Watch for Wysa, Woebot, Limbic, Character.AI, and at least one of the frontier-lab providers (Anthropic, OpenAI, Google) to publish VERA-MH scores within 4–6 weeks. The benchmark's RFC period closes during that window, and the first revised version is likely to harden score interpretability before the Mpathic vs. VERA-MH dual-benchmarking pattern settles. Expect a small wave of methodology critiques of VERA-MH's LLM-as-judge step, mirroring the analogous critique cycle that hit medical LLM evaluation in late 2025.
  • Mid-term: The GBD 2023 adolescent-peak finding will be cited heavily in funding and policy arguments for school-deployed passive-sensing and digital-phenotyping pipelines (Mindcraft, mindLAMP-schools, Beiwe-schools) over the next 12 months. The IHME data is the strongest current denominator for "the cohort we are nominally trying to detect early." Expect at least one major US or UK national funder to issue an adolescent-cohort-specific digital biomarker RFP citing the GBD figures by year-end.
  • Long-term: The combined GBD trajectory (+95.5% prevalence over 33 years, with pandemic-era step changes that have not reverted) and the structural deficit of clinical-workforce capacity make a triage-grade AI screening layer the most plausible high-impact deployment shape — pushing the field's normative target away from autonomous treatment and toward signal-routing into human-clinician care. VERA-MH's design (multi-turn, safety-first, open-source rubric) is well-aligned with that shape; the Mpathic safety benchmark is the parallel commercial-vendor anchor for the same evaluation surface.

Sources used: 8 · Week 3 · Next issue: 30 May 2026